Literature DB >> 3517164

Reversal by lymphokines of the effect of cyclosporin A on contact sensitivity and antibody production in mice.

B Xue, R M Dersarkissian, R L Baer, G J Thorbecke, D V Belsito.   

Abstract

Cyclosporin A (CsA) treatment of mice during the first 4 days of the sensitization phase prevents induction of contact sensitivity to trinitrochlorobenzene (TNCB). Administration of CsA on the day of ear challenge with TNCB also inhibits the effector phase of this response. Simultaneous treatment of the mice with IL 2-containing murine lymphokine preparations or with recombinant human IL 2 reverses the effect of CsA on the induction of contact sensitivity. Recombinant IL 2 also reverses the inhibition by CsA of the effector phase. Neither phase of the response is restored by murine IFN-gamma. Anti-body production to trinitrophenylated (TNP) Ficoll or TNP-hemocyanin is also strongly inhibited (greater than 75%) by CsA injected on the day of antigen injection. Although lymphokines or endotoxin may strongly enhance these responses, no reversal of the effect of CsA can be obtained. We conclude that inhibition of IL 2 production is of paramount importance for the inhibitory effect of CsA on contact sensitivity, but that additional effects are involved in the inhibition of antibody production to both T-dependent and T-independent antigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Effects of topical cyclosporin A on guinea-pig toxic contact dermatitis.

Authors:  M Yokoo; D Oka; S Nakagawa
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Reversal by lymphokines of the age-related hyporesponsiveness to contact sensitization and reduced Ia expression on Langerhans cells.

Authors:  D V Belsito; R M Dersarkissian; G J Thorbecke; R L Baer
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.